Serina Therapeutics, Inc.
SER
$1.56
-$0.08-4.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 130.00K | 116.00K | 130.00K | 51.00K | 56.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.00K | 116.00K | 130.00K | 51.00K | 56.00K |
| Cost of Revenue | 13.16M | 12.12M | 10.88M | 9.33M | 7.48M |
| Gross Profit | -13.03M | -12.00M | -10.75M | -9.27M | -7.42M |
| SG&A Expenses | 11.00M | 9.89M | 10.06M | 9.84M | 8.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.15M | 22.00M | 20.94M | 19.16M | 15.63M |
| Operating Income | -24.02M | -21.89M | -20.81M | -19.11M | -15.57M |
| Income Before Tax | -19.20M | -18.63M | -12.65M | -1.01M | -11.21M |
| Income Tax Expenses | 18.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.22 | -18.63 | -12.65 | -1.01 | -11.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 33.00K | 45.00K | 62.00K | 75.00K | 66.00K |
| Net Income | -19.18M | -18.59M | -12.59M | -939.00K | -11.14M |
| EBIT | -24.02M | -21.89M | -20.81M | -19.11M | -15.57M |
| EBITDA | -23.95M | -21.78M | -20.66M | -18.92M | -15.38M |
| EPS Basic | -1.92 | -1.90 | -1.29 | -0.02 | -4.91 |
| Normalized Basic EPS | -1.18 | -1.07 | -0.70 | 0.09 | -1.39 |
| EPS Diluted | -1.92 | -1.91 | -1.32 | -0.15 | -5.04 |
| Normalized Diluted EPS | -1.18 | -1.07 | -0.71 | 0.01 | -1.47 |
| Average Basic Shares Outstanding | 40.76M | 39.21M | 37.73M | 36.24M | 29.27M |
| Average Diluted Shares Outstanding | 40.76M | 39.21M | 39.63M | 39.78M | 32.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |